Sugi Predict

Sugi Predict / Compounds / SCHEMBL729181

SCHEMBL729181

SCHEMBL729181

CC(C)(C)OC(=O)N1CC[C@@H](OS(C)(=O)=O)[C@@H](F)C1

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.45
▸ RECQL P46063 1/20 0.43
▸ GPR119 Q8TDV5 8/20 0.42
▸ EPHX1 P07099 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ STS P08842 4/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SCN9A Q15858 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL722820 1.00 HPGD (0.45) HPGDRECQLGPR119EPHX1HSD17B10
SCHEMBL29139093 1.00 HPGD (0.45) HPGDRECQLGPR119EPHX1HSD17B10
SCHEMBL729879 1.00 HPGD (0.45) HPGDRECQLGPR119EPHX1HSD17B10
SCHEMBL722821 1.00 HPGD (0.45) HPGDRECQLGPR119EPHX1HSD17B10
SCHEMBL1975622 1.00 HPGD (0.45) HPGDRECQLGPR119EPHX1HSD17B10
SCHEMBL23160580 1.00 HPGD (0.45) HPGDRECQLGPR119EPHX1HSD17B10
SCHEMBL13379071 0.87 HPGD (0.44) HPGDRECQLGPR119EPHX1STS
SCHEMBL12096414 0.87 HPGD (0.44) HPGDRECQLGPR119EPHX1STS
SCHEMBL15866106 0.87 NR1H2 (0.42) HPGDRECQLGPR119EPHX1HSD17B10
SCHEMBL2936192 0.87 HPGD (0.44) HPGDRECQLGPR119EPHX1STS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4288426-B1 QUINOXALINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS INC (US) 2026-02-04 — — EP disclosed
EP-4648763-A2 COMPOUNDS FOR FGFRS INHIBITORS Cogent Biosciences, Inc. (US) 2025-11-19 — — EP disclosed
US-12275731-B2 Azaindole inhibitors of wild-type and mutant forms of LRRK2 DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-04-15 — — US disclosed
US-20240368181-A1 QUINOXALINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS, INC. (US) 2024-11-07 — — US disclosed
US-20240270741-A1 COMPOUNDS FOR FGFRS INHIBITORS COGENT BIOSCIENCES, INC. 2024-08-15 — — US disclosed
WO-2024151638-A2 COMPOUNDS FOR FGFRS INHIBITORS COGENT BIOSCIENCES, INC. (US) 2024-07-18 — — WO disclosed
CN-118027041-A BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof 西藏海思科制药有限公司 2024-05-14 — — CN disclosed
US-11958837-B2 Quinazolinones as PARP14 inhibitors RIBON THERAPEUTICS, INC. (US) 2024-04-16 — — US disclosed
CN-113544130-B BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof 西藏海思科制药有限公司 2024-01-09 — — CN disclosed
EP-4288426-A1 QUINOXALINE DERIVATIVES AND USES THEREOF Black Diamond Therapeutics, Inc. (US) 2023-12-13 — — EP disclosed
US-8575145-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-11-05 — — US disclosed
EP-2334677-B1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2013-10-09 — — EP disclosed
EP-2137184-B1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2013-05-08 — — EP disclosed
US-8138181-B2 Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2012-03-20 — — US disclosed
EP-2334677-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS Array Biopharma, Inc. (US) 2011-06-22 — — EP disclosed
US-20110144085-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-06-16 — — US disclosed
WO-2010022076-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-02-25 — — WO disclosed
US-20100029633-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-02-04 — — US disclosed
EP-2137184-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2009-12-30 — — EP disclosed
WO-2008124323-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2008-10-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029633-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS PIM1, PIM3, PIM2 HPGD 4548/4885RECQL 2231/4885GPR119 386/4885
US-11958837-B2 Quinazolinones as PARP14 inhibitors PARP14, PARP15, PARP11 HPGD 658/4885RECQL 538/4885GPR119 3964/4885
US-20240270741-A1 COMPOUNDS FOR FGFRS INHIBITORS FGFR1, FGFR3, FGFR2 HPGD 4566/4885RECQL 1460/4885GPR119 89/4885
US-12275731-B2 Azaindole inhibitors of wild-type and mutant forms of LRRK2 LRRK2, PARK7, GDI2 HPGD 1441/4885RECQL 448/4885GPR119 1692/4885
US-20110144085-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 HPGD 4505/4885RECQL 2306/4885GPR119 237/4885
US-20240368181-A1 QUINOXALINE DERIVATIVES AND USES THEREOF NQO2, NQO1, GLS HPGD 143/4885RECQL 14/4885GPR119 1490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.